Clinical Trials Browser

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT00861705 2025-09-30

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Phase 2 Completed

454 enrolled 23 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT00070564 2025-07-31

S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer

Phase 3 Active not recruiting

3,294 enrolled 22 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT01147016 2023-04-27

Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery

Phase 2 Terminated

8 enrolled 7 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT00436566 2022-08-05

Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery

Phase 2 Completed

122 enrolled 22 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male, Cardiotoxicity

NCT00470301 2021-02-16

Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer

Phase 1/2 Completed

60 enrolled 6 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00616122 2020-01-13

Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast Cancer

Phase 1/2 Terminated

32 enrolled 10 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00513695 2019-08-07

Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer

Phase 2 Completed

68 enrolled 10 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

NCT00971737 2019-04-24

Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer

Phase 2 Completed

63 enrolled 8 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00847171 2018-09-26

Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer

Phase 2 Completed

20 enrolled 6 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00376805 2017-12-28

Allogeneic Natural Killer (NK) Cells in Patients With Advanced Metastatic Breast Cancer

Phase 2 Terminated

6 enrolled 9 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00331552 2017-07-26

Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer

Phase 1/2 Completed

30 enrolled 13 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00343863 2017-07-11

Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer

Phase NA Completed

41 enrolled 12 charts

Breast

Breast Neoplasms, Nausea, Vomiting, Breast Neoplasms, Male

NCT00791037 2017-05-25

Vaccine Therapy in Treating Patients With Stage IV Breast Cancer

Phase 1/2 Completed

23 enrolled 9 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00482391 2017-05-12

Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer

Phase 2 Completed

95 enrolled 7 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00182793 2017-02-23

Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer

Phase 2 Completed

32 enrolled 6 charts

Breast

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Lobular, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

NCT00119262 2014-05-15

Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer

Phase 2 Completed

226 enrolled 8 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male

Clinical Trials

Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer

Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery

Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery

Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer

Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast Cancer

Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer

Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer

Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer

Allogeneic Natural Killer (NK) Cells in Patients With Advanced Metastatic Breast Cancer

Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer

Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer

Vaccine Therapy in Treating Patients With Stage IV Breast Cancer

Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer

Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer

Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer